Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (161-170 of 662) with videos related to

Pageof 67
Sort By:
Experimental Hematology|January 3, 2007
Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophilsMaria-Theresa Krauth, Alexandra Böhm, Hermine Agis, et al.
European Journal of Haematology|October 4, 2022
Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian populationIrene Graf, Susanne Herndlhofer, Michael Kundi, et al.
American Journal of Hematology|May 4, 2011
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CMLKarl J Aichberger, Susanne Herndlhofer, Gerit-Holger Schernthaner, et al.
Leukemia Research|December 23, 2003
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literatureAlexander W Hauswirth, Ingrid Simonitsch-Klupp, Martin Uffmann, et al.
Wiener Klinische Wochenschrift|November 7, 2008
[Individualized management and therapy of myelodysplastic syndromes]Reinhard Stauder, Friedrich Wimazal, Thomas Nösslinger, et al.
Plos One|February 21, 2012
Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft modelDaniel Wicklein, Nuno Ramos Leal, Johannes Salamon, et al.
American Journal of Cancer Research|February 12, 2021
Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancerKarin Bauer, Anna S Berghoff, Matthias Preusser, et al.
European Journal of Immunology|September 5, 2002
Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibodySabine Flicker, Peter Steinberger, Lars Norderhaug, et al.
International Journal of Molecular Sciences|March 6, 2021
Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and BeyondBettina Sprinzl, Georg Greiner, Goekhan Uyanik, et al.
Thrombosis Research|November 30, 2004
Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosisSophie Ziegler, Wolfgang R Sperr, Paul Knöbl, et al.
Pageof 67

Showing results (161-170 of 662) with videos related to

Sort By:
Pageof 67
Experimental Hematology|January 3, 2007
Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophilsMaria-Theresa Krauth, Alexandra Böhm, Hermine Agis, et al.
European Journal of Haematology|October 4, 2022
Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian populationIrene Graf, Susanne Herndlhofer, Michael Kundi, et al.
American Journal of Hematology|May 4, 2011
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CMLKarl J Aichberger, Susanne Herndlhofer, Gerit-Holger Schernthaner, et al.
Leukemia Research|December 23, 2003
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literatureAlexander W Hauswirth, Ingrid Simonitsch-Klupp, Martin Uffmann, et al.
Wiener Klinische Wochenschrift|November 7, 2008
[Individualized management and therapy of myelodysplastic syndromes]Reinhard Stauder, Friedrich Wimazal, Thomas Nösslinger, et al.
Plos One|February 21, 2012
Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft modelDaniel Wicklein, Nuno Ramos Leal, Johannes Salamon, et al.
American Journal of Cancer Research|February 12, 2021
Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancerKarin Bauer, Anna S Berghoff, Matthias Preusser, et al.
European Journal of Immunology|September 5, 2002
Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibodySabine Flicker, Peter Steinberger, Lars Norderhaug, et al.
International Journal of Molecular Sciences|March 6, 2021
Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and BeyondBettina Sprinzl, Georg Greiner, Goekhan Uyanik, et al.
Thrombosis Research|November 30, 2004
Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosisSophie Ziegler, Wolfgang R Sperr, Paul Knöbl, et al.
Pageof 67